April 15, 2017
BioCentury
By Stephen Hansen
While investors, media and even some payers have been touting the pricing of three recently launched drugs as
sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But they
are likely to result in lower co-pays for patients, which could increase access.
